Rapamycin: The mTOR Story Everyone in Longevity Is Watching

Rapamycin was originally developed and FDA-approved as an immunosuppressant for organ transplant recipients, working by inhibiting a cellular signaling pathway called mTOR, mechanistic target of rapamycin, which regulates cell growth, metabolism, and autophagy. In laboratory studies, rapamycin has consistently extended lifespan across multiple species including mice, making it one of the most replicated longevity interventions in animal research.

Human data remains much more limited than the animal literature, and the immunosuppressive effects that make it useful for transplant patients raise real questions about long-term use in healthy people, particularly around infection risk. Researchers studying off-label, low-dose rapamycin use for longevity purposes are actively trying to determine whether intermittent, lower dosing can capture the mTOR-inhibition benefits seen in animal studies while minimizing the immunosuppression that comes with the doses used in transplant medicine.

Why this matters for tracking: rapamycin represents one of the more scientifically grounded longevity interventions in terms of animal data, but the human safety and dosing picture is still being actively worked out.